Incluye referencias bibliográficas

Preface; References; Contents; Part I: Diagnosis; Chapter 1: Classification of Adenocarcinoma of the Lung, with a Special Reference to Prognosis; 1.1 Classification of Adenocarcinoma of the Lung in New WHO Classification; 1.1.1 Introduction: Major Changes in the Classification; 1.1.2 Preinvasive Lesions; 1.1.2.1 Atypical Adenomatous Hyperplasia (AAH) (Fig. 1.1); 1.1.2.2 Adenocarcinoma In Situ (AIS) (Fig. 1.2); 1.1.3 Minimally Invasive Adenocarcinoma (MIA) (Fig. 1.4); 1.1.4 Invasive Adenocarcinoma (Fig. 1.3) (Table 1.2); 1.1.4.1 Lepidic Adenocarcinoma (Fig. 1.5).

1.1.4.2 Acinar Adenocarcinoma (Fig. 1.6)1.1.4.3 Papillary Adenocarcinoma (Fig. 1.7); 1.1.4.4 Micropapillary Adenocarcinoma (Fig. 1.8); 1.1.4.5 Solid Adenocarcinoma (Fig. 1.9); 1.1.5 Variants of Adenocarcinoma; 1.1.5.1 Invasive Mucinous Adenocarcinoma (IMA) (Fig. 1.10); 1.1.5.2 Colloid Adenocarcinoma (Fig. 1.11); 1.1.5.3 Fetal Adenocarcinoma (Fig. 1.12); 1.1.5.4 Enteric Adenocarcinoma (Fig. 1.13); References; Chapter 2: Screening Lung Cancer with Low-Dose CT Combined with Molecular Markers; 2.1 Introduction; 2.2 History of Study on Early Detection of Lung Cancer with CT.

2.2.1 Single-Arm Retrospective or Prospective Studies2.2.2 Small-Scale Randomized Studies; 2.3 Major Outcomes of the NLST; 2.3.1 The First Positive Study of a Large-Scale Randomized Study; 2.3.2 Post Hoc Analyses of the NLST; 2.3.3 Implementation of LDCT as a Public Health-Care Program in the USA; 2.4 Future Directions Beyond CT Screening; 2.4.1 Computer-Aided Evaluation of CT Screening; 2.4.2 Molecular Marker-Assisted Lung Cancer Screening with LDCT; 2.5 Conclusion; References; Chapter 3: PET-CT, Bio-imaging for Predicting Prognosis and Response to Chemotherapy in Patients with Lung Cancer.

3.1 Introduction3.2 Prognostic Variables in Patients with Lung Cancer; 3.3 Biological Significance of 18F-FDG-PET; 3.4 Clinical Role of 18F-FDG-PET as a Predictor of Outcome After Chemotherapy; 3.5 False-Positive Findings in 18F-FDG-PET; 3.6 Development of Tumor-Specific PET Tracers; 3.7 Clinical Significance of 18F-FAMT-PET; 3.8 Prognostic Significance of LAT1 Expression; 3.9 Summary and Conclusion; References; Chapter 4: Methods in Molecular Diagnosis; 4.1 Genomic Alterations in Lung Cancer [1]; 4.2 Concept of the Driver Mutations; 4.3 Important Driver Genes.

4.3.1 The mutated Epidermal Growth Factor Receptor (EGFR) Gene4.3.2 The mutated v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Gene; 4.3.3 The Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK)-Fusion Gene; 4.3.4 The mutated BRAF Gene, the ROS1-Fusion Genes, and the RET-Fusion Genes; 4.4 Specimen Used for the Molecular Diagnosis of Lung Cancer; 4.5 Methods; 4.5.1 PCR-Based Methods; 4.5.2 RT-PCR-Based Methods; 4.5.3 Next-Generation Sequencing (NGS); 4.5.4 Utilization of Liquid Biopsy Samples; 4.5.5 FISH (Fluorescent In Situ Hybridization); 4.5.6 Immunohistochemistry (IHC).

This book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wide variety of resistance mechanisms using new-generation molecular targeted agents and potential novel approaches. It also outlines the increasing necessity for new diagnostic technology and strategies for managing different adverse effects and novel methods for evaluating effectiveness and safety. Edited and authored by opinion leaders, Molecular Targeted Therapy of Lung Cancer provides a comprehensive overview of the disease and its treatments. It is a valuable resource for graduate students, post-doctoral fellows and faculty staff, as well as researchers involved in clinical and translational research on lung cancer, helping promote new ideas for further advances.